PT -期刊文章盟艾丽卡伯德盟凯萨琳Albers AU -塞缪尔高盛盟Jeffrey Klingman AU - Raymond Lo盟康尼马拉AU -紫水晶Leimpeter AU -罗宾Fross盟凯萨琳Comyns盟Zhuqin顾AU -玛雅Katz盟劳丽Ozelius盟-苏珊Bressman AU -瑞秋Saunders-Pullman盟辛西娅·考米拉盟Lorene Nelson AU -斯蒂芬·范Eeden盟卡罗琳·坦纳TI -睑痉挛的多民族人口(P3.348) DP - 2016年4月05 TA -神经病学PG - P3.348 VI - 86 IP - 16补充4099 - //www.ez-admanager.com/content/86/16_Supplement/P3.348.short 4100 - //www.ez-admanager.com/content/86/16_Supplement/P3.348.full所以Neurology2016 4月05;首页86 AB -目的:确定无力睑痉挛的发生率和前期诊断特征在一个大型的、多民族的综合健康维护组织。背景:睑痉挛发生率有有限的数据和之前的报告都是基于少数病例。Design/methods: Incident blepharospasm cases were identified using electronic medical record review in >3 million members of Kaiser Permanente Northern California (KPNC) during 2003-2007. Final diagnosis was determined by consensus of two movement disorders specialists. Incidence rates were standardized using the 2000 U.S. Census population. Controls were matched for age, sex and membership duration (1 case: 10 controls). Odds ratios were determined using logistic regression adjusted for age, gender and membership duration. Results: Blepharospasm incidence standardized to the U.S. 2000 Census population was 1.45/100,000 person-years (95[percnt] CI, 0.53 to 2.37; women: 2.05, men: 0.83) based on 246 cases over 15.4 million person-years of risk. Incidence increased with age through the eighth decade and was highest in Caucasians (1.58) followed by Asians (1.32), African Americans (1.08) and Native Americans (0.95). Ocular diagnoses more common in patients with blepharospasm compared to controls before index date included were eye allergy (OR 2.82, 95[percnt] CI, 1.69 to 4.7), dry eyes (OR 9.19, 95[percnt] CI, 6.22 to 13.58), glaucoma (OR 2.76, 95[percnt] CI, 1.28 to 5.95), eye injury (OR 2.38, 95[percnt] CI, 1.44 to 3.94) and eye infection (OR 3.76, 95[percnt] CI, 2.58 to 5.47). Conclusions: Blepharospasm incidence is higher in women, in those of increasing age and of Caucasian race. Diagnoses preceding blepharospasm may reflect comorbid conditions, diagnostic errors or etiologic factors. Support: NIH-1R01-NS046340, AHRQ-R01-HS018413, Dystonia Medical Research Foundation, KPNC, James and Sharron ClarkDisclosure: Dr. Byrd has nothing to disclose. Dr. Albers has nothing to disclose. Dr. Goldman has nothing to disclose. Dr. Klingman has nothing to disclose. Dr. Lo has nothing to disclose. Dr. Marras has nothing to disclose. Dr. Leimpeter has nothing to disclose. Dr. Fross has nothing to disclose. Dr. Comyns has nothing to disclose. Dr. Gu has nothing to disclose. Dr. Katz has nothing to disclose. Dr. Ozelius has nothing to disclose. Dr. Bressman has nothing to disclose. Dr. Saunders-Pullman has nothing to disclose. Dr. Comella has received personal compensation for activities with Ipsen, Merz, Allergan, Medtronic, Teva, US World Meds, Impax, Acadia, Acorda, Revance, Neurocrine, and Ultragenx Pharmaceuticals as a consultant. Dr. Comella has received research support Dr. Nelson has received compensation from Neuropace Inc. for service on a DSMB, and from Acumen, LLC for epidemiology consulting. Dr. Van Den Eeden has nothing to disclose. Dr. Tanner has received personal compensation for activities with Neurocrine and Ultragenyx Pharmaceuticals as a consultant.Monday, April 18 2016, 8:30 am-7:00 pm